Known targets — ChEMBL curated mechanism
MMP1MMP13MMP7MMP8polrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Decylamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 9/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.81 |
| ▸ | TSHR | P16473 | 3/20 | 0.81 |
| ▸ | MEN1 | O00255 | 2/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.81 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.81 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA3 | P07451 | 1/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | CA6 | P23280 | 1/20 | 0.50 |
| ▸ | CA5A | P35218 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alcohol SCHEMBL11466733 | 1.00 | DNM1 (0.81) | DNM1ALDH1A1TSHRMEN1KMT2A | |
| Alcohol SCHEMBL11462091 | 1.00 | DNM1 (0.81) | DNM1ALDH1A1TSHRMEN1KMT2A | |
| Octadecylamine SCHEMBL9460974 | 1.00 | DNM1 (0.81) | DNM1ALDH1A1TSHRMEN1KMT2A | |
| Tetradecylamine SCHEMBL238293 | 1.00 | DNM1 (0.81) | DNM1ALDH1A1TSHRMEN1KMT2A | |
| Pentadecylamine SCHEMBL11453009 | 1.00 | DNM1 (0.81) | DNM1ALDH1A1TSHRMEN1KMT2A | |
| Hexadecylamine SCHEMBL3962485 | 1.00 | DNM1 (0.81) | DNM1ALDH1A1TSHRMEN1KMT2A | |
| Alcohol SCHEMBL474302 | 1.00 | DNM1 (0.81) | DNM1ALDH1A1TSHRMEN1KMT2A | |
| Alcohol SCHEMBL11455986 | 1.00 | DNM1 (0.81) | DNM1ALDH1A1TSHRMEN1KMT2A | |
| Alcohol SCHEMBL11471709 | 1.00 | DNM1 (0.81) | DNM1ALDH1A1TSHRMEN1KMT2A | |
| Alcohol SCHEMBL10812415 | 1.00 | DNM1 (0.81) | DNM1ALDH1A1TSHRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115724761-A | Janus type nano graphene oxide, thickened oil viscosity reducer and preparation method thereof | 中国石油化工股份有限公司 | 2023-03-03 | — | — | CN | disclosed |
| CN-111233713-A | Synthesis method of telavancin intermediate | 福建康鸿生物科技有限公司 | 2020-06-05 | — | — | CN | disclosed |
| CN-102596243-A | Nanoemulsion vaccines | UNIV MICHIGAN | 2012-07-18 | — | — | CN | disclosed |
| WO-2011005959-A1 | PROCESS FOR THE PREPARATION OF N-PROTECTED-DECYLAMINOETHANAL | PLUS CHEMICALS SA (CH) | 2011-01-13 | — | — | WO | disclosed |
| US-20110009596-A1 | PROCESS FOR THE PREPARATION OF N-PROTECTED-DECYLAMINOETHANAL | PLUS CHEMICALS SA (CH) | 2011-01-13 | — | — | US | disclosed |
| US-4223138-A | VAPORIZATION, CONDENSATION, RETARDING FLOW TO REACTION ZONE | BAYER AKTIENGESELLSCHAFT (DE) | 1980-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009596-A1 | PROCESS FOR THE PREPARATION OF N-PROTECTED-DECYLAMINOETHANAL | PTMA, DNPEP, TET2 | DNM1 1951/4885ALDH1A1 3092/4885TSHR 3441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.